"From the last annual review conducted a few days ago by the board of directors of the European Medicines Agency (EMA) it emerged that Italy, in the last three years, has climbed many positions" among the most important countries in the sector for European pharmaceutical policy, "and is one of the EU states most on the rise, with an extremely encouraging trend".
Guido Rasi, executive director of the European Medicines Agency (EMA), told Pharmakronos in Rome on the sidelines of the Graduation Day of the Altems training programs at the Catholic University of the Sacred Heart, where he gave a masterful lecture.
"There are some weaknesses - Rasi points out - in pharmacovigilance, also because we have implemented the European legislation on the subject differently from others. Italy's influence is growing: it is reaping the fruits of the last 3-4 years of work, the last 2 managed particularly well. I hope it will continue, also because other countries are declining and Italy could conquer a leadership position.
This is crucial because when we help make decisions and are in a leadership position, we do so with an eye to our national health system. And this is not in dissonance with the work of others: everyone does it with respect to the country where they live and for this reason we were subjected to decisions made on a scale with other health systems.
Our influence is therefore decisive on what we find at home".
Barbara DiChiara – April 12, 2013 – PharmaKronos
